Table 3 Results of multivariate survival analysis
From: Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer
Characteristic | Baseline model (N=323) | Chemotherapy response-based model (N=233) | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | |
Gender (female vs male) | 1.71 | 1.33-2.19 | <0.001 | 1.40 | 1.01-1.94 | 0.039 |
KPS (70~80 vs 90~100) | 0.68 | 0.49-0.94 | 0.018 | 0.57 | 0.40-0.80 | 0.001 |
Ascites | NI | 1.47 | 1.04-2.08 | 0.031 | ||
Baseline WBC | 1.55 | 1.17-2.06 | 0.002 | NI | ||
Baseline N | 1.35 | 1.03-1.78 | 0.032 | 1.56 | 1.14-2.13 | 0.005 |
Baseline TB | 1.44 | 1.09-1.91 | 0.012 | NI | ||
Baseline CA 19-9 | 1.87 | 1.41-2.47 | <0.001 | 1.70 | 1.21-2.38 | 0.002 |
Baseline CEA | NI | 1.54 | 1.09-2.19 | 0.017 | ||
Change in CA19–9 level at week 6 | NI | |||||
Decrease | Ref | |||||
No change or increase | 1.51 | 1.06-2.14 | 0.017 | |||
Change in CEA level at week 6 | NI | |||||
Decrease | Ref | |||||
No change or increase | 1.48 | 1.02-2.14 | 0.039 | |||
Initial response to chemotherapy | NI | |||||
PD | Ref | |||||
Non-PD | 0.46 | 0.31-0.69 | <0.001 | |||